Osama O Zaidat1, Hormozd Bozorgchami2, Marc Ribó3, Jeffrey L Saver4, Heinrich P Mattle5, René Chapot6, Ana Paula Narata7, Olivier Francois8, Ashutosh P Jadhav9, Jonathan A Grossberg10, Christian H Riedel11, Alejandro Tomasello12, Wayne M Clark2, Hannes Nordmeyer6, Eugene Lin13, Raul G Nogueira10, Albert J Yoo14, Tudor G Jovin9, Adnan H Siddiqui15, Thierry Bernard16, Mairsíl Claffey17, Tommy Andersson3,8. 1. From the Department of Neuroscience, Mercy St. Vincent Medical Center, Toledo, OH (O.O.Z., E.L.) oozaidat@mercy.com. 2. Oregon Health and Science University Hospital, Portland (H.B., W.M.C.). 3. Department of Neuroradiology, Vall d'Hebron University Hospital, Barcelona, Spain (M.R., A.T.). 4. Department of Neurology, David Geffen School of Medicine, University of California, Los Angeles (J.L.S.). 5. Department of Neurology, Inselspital, University of Bern, Switzerland (H.P.M.). 6. Department of Radiology and Neuroradiology, Alfried Krupp Krankenhaus, Essen, Germany (R.C., H.N.). 7. Centre Hospitalier Régional Universitaire, Hôpitaux de Tours, France (A.P.N.). 8. AZ Groeninge, Kortrijk, Belgium (O.F., T.A.). 9. Department of Neurology, University of Pittsburgh Medical Center, PA (A.P.J., T.G.J.). 10. Department of Neurosurgery, Emory University School of Medicine, Atlanta, GA (J.A.G., R.G.N.). 11. Universitätsklinikum Schleswig-Holstein, Kiel Campus, Germany (C.H.R.). 12. Department of Neuroradiology, Karolinska University Hospital, Karolinska Institute, Stockholm, Sweden (T.A.). 13. From the Department of Neuroscience, Mercy St. Vincent Medical Center, Toledo, OH (O.O.Z., E.L.). 14. Department of Interventional Radiology, Texas Stroke Institute, Dallas-Fort Worth (A.J.Y.). 15. Department of Neurosurgery, University of Buffalo, NY (A.H.S.). 16. Johnson & Johnson, Warsaw, IN (T.B.). 17. Neuravi, Galway, Ireland (M.C.).
Abstract
BACKGROUND AND PURPOSE: EmboTrap is a novel stent retriever designed to achieve rapid and substantial flow restoration in acute ischemic stroke secondary to large-vessel occlusions. Here, we evaluated EmboTrap's safety and efficacy compared with established stent retrievers. METHODS: ARISE II (Analysis of Revascularization in Ischemic Stroke With EmboTrap) was a single-arm, prospective, multicenter study, comparing the EmboTrap device to a composite performance goal criterion derived using a Bayesian meta-analysis from the pivotal SWIFT (Solitaire device) and TREVO 2 (Trevo device) trials. Patients at 11 US and 8 European sites were eligible for inclusion if they had large-vessel occlusions and moderate-to-severe neurological deficits within 8 hours of symptom onset. The primary efficacy end point was achievement of modified Thrombolysis in Cerebral Ischemia (mTICI) reperfusion scores of ≥2b within 3 EmboTrap passes as adjudicated by the core laboratory. The primary safety end point was a composite of symptomatic intracerebral hemorrhage and serious adverse device effects. Secondary end points included functional independence (modified Rankin Scale, 0-2) and all-cause mortality at 90 days. RESULTS: Between October 2015 and February 2017, 227 patients were enrolled and treated with the EmboTrap device. The primary efficacy end point (mTICI ≥2b within 3 passes) was achieved in 80.2% (95% confidence interval, 74%-85% versus 56% performance goal criterion; P value, <0.0001), and mTICI 2c/3 was 65%. After all interventions, mTICI 2c/3 was achieved in 76%, and mTICI ≥2b was 92.5%. The rate of first pass (mTICI ≥2b following a single pass) was 51.5%. The primary safety end point composite rate of symptomatic intracerebral hemorrhage or serious adverse device effects was 5.3%. Functional independence and all-cause mortality at 90 days were 67% and 9%, respectively. CONCLUSIONS: The EmboTrap stent-retriever mechanical thrombectomy device demonstrated high rates of substantial reperfusion and functional independence in patients with acute ischemic stroke secondary to large-vessel occlusions. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT02488915.
BACKGROUND AND PURPOSE: EmboTrap is a novel stent retriever designed to achieve rapid and substantial flow restoration in acute ischemic stroke secondary to large-vessel occlusions. Here, we evaluated EmboTrap's safety and efficacy compared with established stent retrievers. METHODS: ARISE II (Analysis of Revascularization in Ischemic Stroke With EmboTrap) was a single-arm, prospective, multicenter study, comparing the EmboTrap device to a composite performance goal criterion derived using a Bayesian meta-analysis from the pivotal SWIFT (Solitaire device) and TREVO 2 (Trevo device) trials. Patients at 11 US and 8 European sites were eligible for inclusion if they had large-vessel occlusions and moderate-to-severe neurological deficits within 8 hours of symptom onset. The primary efficacy end point was achievement of modified Thrombolysis in Cerebral Ischemia (mTICI) reperfusion scores of ≥2b within 3 EmboTrap passes as adjudicated by the core laboratory. The primary safety end point was a composite of symptomatic intracerebral hemorrhage and serious adverse device effects. Secondary end points included functional independence (modified Rankin Scale, 0-2) and all-cause mortality at 90 days. RESULTS: Between October 2015 and February 2017, 227 patients were enrolled and treated with the EmboTrap device. The primary efficacy end point (mTICI ≥2b within 3 passes) was achieved in 80.2% (95% confidence interval, 74%-85% versus 56% performance goal criterion; P value, <0.0001), and mTICI 2c/3 was 65%. After all interventions, mTICI 2c/3 was achieved in 76%, and mTICI ≥2b was 92.5%. The rate of first pass (mTICI ≥2b following a single pass) was 51.5%. The primary safety end point composite rate of symptomatic intracerebral hemorrhage or serious adverse device effects was 5.3%. Functional independence and all-cause mortality at 90 days were 67% and 9%, respectively. CONCLUSIONS: The EmboTrap stent-retriever mechanical thrombectomy device demonstrated high rates of substantial reperfusion and functional independence in patients with acute ischemic stroke secondary to large-vessel occlusions. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT02488915.
Authors: Heinrich P Mattle; Carl Scarrott; Mairsil Claffey; John Thornton; Juan Macho; Christian Riedel; Michael Söderman; Alain Bonafé; Michel Piotin; John Newell; Tommy Andersson Journal: Interv Neuroradiol Date: 2018-12-18 Impact factor: 1.610
Authors: Philipp Gruber; Michael Diepers; Alexander von Hessling; Johannes Weber; Timo Kahles; Javier Anon; Jatta Berberat; Krassen Nedeltchev; David S Liebeskind; Luca Remonda Journal: Interv Neuroradiol Date: 2020-07-27 Impact factor: 1.610
Authors: Volker Maus; Silja Henkel; Alexander Riabikin; Christian Riedel; Daniel Behme; Ioannis Tsogkas; Amelie Carolina Hesse; Nuran Abdullayev; Olav Jansen; Martin Wiesmann; Anastasios Mpotsaris; Marios-Nikos Psychogios Journal: Clin Neuroradiol Date: 2018-07-19 Impact factor: 3.649
Authors: Marion Boulanger; Bertrand Lapergue; Francis Turjman; Emmanuel Touzé; René Anxionnat; Serge Bracard; Michel Piotin; Benjamin Gory Journal: Interv Neuroradiol Date: 2019-02-04 Impact factor: 1.610
Authors: Giulia Luraghi; Jose Felix Rodriguez Matas; Gabriele Dubini; Francesca Berti; Sara Bridio; Sharon Duffy; Anushree Dwivedi; Ray McCarthy; Behrooz Fereidoonnezhad; Patrick McGarry; Charles B L M Majoie; Francesco Migliavacca Journal: Interface Focus Date: 2020-12-11 Impact factor: 3.906
Authors: A Srivatsan; V M Srinivasan; R M Starke; E C Peterson; D R Yavagal; A E Hassan; A Alawieh; A M Spiotta; Y Saleem; K M Fargen; S Q Wolfe; R A de Leacy; I P Singh; I L Maier; J N Johnson; J-K Burkhardt; S R Chen; P Kan Journal: AJNR Am J Neuroradiol Date: 2021-03-11 Impact factor: 3.825
Authors: Adam de Havenon; Ana Paula Narata; Aymeric Amelot; Jeffrey L Saver; Hormozd Bozorgchami; Heinrich Paul Mattle; Marc Ribo; Tommy Andersson; Osama O Zaidat Journal: J Neurointerv Surg Date: 2020-11-20 Impact factor: 5.836